These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35571388)

  • 1. Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China.
    Wang Z; Sun R; Sheng Y; Qu S; Dong L; Wu B
    Ann Transl Med; 2022 Apr; 10(8):480. PubMed ID: 35571388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan.
    Habu Y
    Intern Med; 2019 Sep; 58(17):2427-2433. PubMed ID: 31178490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
    Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
    Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment strategies for reflux esophagitis including a potassium-competitive acid blocker: A cost-effectiveness analysis in Japan.
    Habu Y; Hamasaki R; Maruo M; Nakagawa T; Aono Y; Hachimine D
    J Gen Fam Med; 2021 Sep; 22(5):237-245. PubMed ID: 34484992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis.
    Hoshino S; Kawami N; Takenouchi N; Umezawa M; Hanada Y; Hoshikawa Y; Kawagoe T; Sano H; Hoshihara Y; Nomura T; Iwakiri K
    Digestion; 2017; 95(2):156-161. PubMed ID: 28190016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Vonoprazan for 48-Week Maintenance Therapy of Patients with Healed Reflux Esophagitis.
    Mizuno H; Nishino M; Yamada K; Kamiyamamoto S; Hinoue Y
    Digestion; 2020; 101(4):411-421. PubMed ID: 31129668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.
    Gotoh Y; Ishibashi E; Honda S; Nakaya T; Noguchi C; Kagawa K; Murakami K
    Medicine (Baltimore); 2020 Mar; 99(11):e19520. PubMed ID: 32176102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD.
    Yokoya Y; Igarashi A; Uda A; Deguchi H; Takeuchi T; Higuchi K
    J Gastroenterol; 2019 Dec; 54(12):1083-1095. PubMed ID: 31396703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Vonoprazan for Refractory Reflux Esophagitis after Esophagectomy.
    Ochiai Y; Iizuka T; Hoshihara Y; Suzuki Y; Hayasaka J; Nomura K; Tanaka M; Odagiri H; Yamashita S; Matsui A; Kikuchi D; Ueno M; Udagawa H; Hoteya S
    Dig Dis; 2021; 39(6):569-576. PubMed ID: 33567428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety and cost-effectiveness of vonoprazan vs Proton Pump Inhibitors in reflux disorders and H. pylori eradication: A literature review.
    Shehryar M; Ahmad RU; Kareem HK; Khan L; Ashraf MF; Hassan A; Saeed S; Tareen HK; Nazir DA; Ashraf MA
    Ann Med Surg (Lond); 2022 Oct; 82():104760. PubMed ID: 36268393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors.
    Mizuno H; Yamada K; Minouchi K; Kamiyamamoto S; Hinoue Y
    Biomed Rep; 2018 Feb; 8(2):148-155. PubMed ID: 29435273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China.
    Zhang Z; Bao Y; Cai L; Gu Y; Yang T; Li X
    Clin Drug Investig; 2022 Oct; 42(10):839-851. PubMed ID: 35994227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
    Kajihara Y; Shimoyama T; Mizuki I
    Scand J Gastroenterol; 2017 Feb; 52(2):238-241. PubMed ID: 27806639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Ameliorating Effect of Switching to Vonoprazan: A Novel Potassium-Competitive Acid Blocker in Patients with Proton Pump Inhibitor Refractory Non-Erosive Reflux Disease.
    Abe Y; Koike T; Saito M; Okata T; Nakagawa K; Hatta W; Asanuma K; Uno K; Asano N; Imatani A; Masamune A
    Digestion; 2021; 102(3):480-488. PubMed ID: 32062650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia.
    Asaoka D; Nagahara A; Hojo M; Matsumoto K; Ueyama H; Matsumoto K; Izumi K; Takeda T; Komori H; Akazawa Y; Shimada Y; Osada T; Watanabe S
    Biomed Rep; 2017 Feb; 6(2):175-180. PubMed ID: 28357069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes of Vonoprazan-Treated Patients after Endoscopic Submucosal Dissection for Gastric Neoplasms: A Prospective Multicenter Observation Study.
    Ishida T; Dohi O; Yamada S; Yasuda T; Yamada N; Tomie A; Tsuji T; Horii Y; Majima A; Horie R; Fukui A; Zen K; Tomatsuri N; Yagi N; Naito Y; Itoh Y
    Digestion; 2021; 102(3):386-396. PubMed ID: 32585678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Vonoprazan vs. Intravenous Proton Pump Inhibitor in Prevention of Re-Bleeding of High-Risk Peptic Ulcers: A Randomized Controlled Pilot Study.
    Pattarapuntakul T; Wong T; Wetwittayakhlang P; Netinatsunton N; Keeratichananont S; Kaewdech A; Jandee S; Chamroonkul N; Sripongpun P; Lakatos PL
    J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38930134
    [No Abstract]   [Full Text] [Related]  

  • 18. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
    Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
    Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of proton pump inhibitors and vonoprazan on the development of 'gastric mucosal redness'.
    Shinozaki S; Osawa H; Miura Y; Hayashi Y; Sakamoto H; Yano T; Kawarai Lefor A; Yamamoto H
    Biomed Rep; 2022 Jun; 16(6):51. PubMed ID: 35620314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.
    Ashida K; Sakurai Y; Nishimura A; Kudou K; Hiramatsu N; Umegaki E; Iwakiri K; Chiba T
    Aliment Pharmacol Ther; 2015 Sep; 42(6):685-95. PubMed ID: 26201312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.